Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NKG2D Polymorphism in Melanoma Patients from Southeastern Spain.
Gimeno L, Martínez-Banaclocha H, Bernardo MV, Bolarin JM, Marín L, López-Hernández R, López-Alvarez MR, Moya-Quiles MR, Muro M, Frias-Iniesta JF, Martínez-Escribano J, Alvarez-López MR, Minguela A, Campillo JA. Gimeno L, et al. Among authors: lopez alvarez mr. Cancers (Basel). 2019 Mar 28;11(4):438. doi: 10.3390/cancers11040438. Cancers (Basel). 2019. PMID: 30925758 Free PMC article.
NK Cell Education in Tumor Immune Surveillance: DNAM-1/KIR Receptor Ratios as Predictive Biomarkers for Solid Tumor Outcome.
Guillamón CF, Martínez-Sánchez MV, Gimeno L, Mrowiec A, Martínez-García J, Server-Pastor G, Martínez-Escribano J, Torroba A, Ferri B, Abellán D, Campillo JA, Legaz I, López-Álvarez MR, Moya-Quiles MR, Muro M, Minguela A. Guillamón CF, et al. Among authors: lopez alvarez mr. Cancer Immunol Res. 2018 Dec;6(12):1537-1547. doi: 10.1158/2326-6066.CIR-18-0022. Epub 2018 Sep 21. Cancer Immunol Res. 2018. PMID: 30242020
Activating KIRs on Educated NK Cells Support Downregulation of CD226 and Inefficient Tumor Immunosurveillance.
Guillamón CF, Martínez-Sánchez MV, Gimeno L, Campillo JA, Server-Pastor G, Martínez-García J, Martínez-Escribano J, Torroba A, Ferri B, Abellán DJ, Legaz I, López-Álvarez MR, Moya-Quiles MR, Muro M, Minguela A. Guillamón CF, et al. Among authors: lopez alvarez mr. Cancer Immunol Res. 2019 Aug;7(8):1307-1317. doi: 10.1158/2326-6066.CIR-18-0847. Epub 2019 Jun 25. Cancer Immunol Res. 2019. PMID: 31239317
KIR gene variability in cutaneous malignant melanoma: influence of KIR2D/HLA-C pairings on disease susceptibility and prognosis.
Campillo JA, Legaz I, López-Álvarez MR, Bolarín JM, Las Heras B, Muro M, Minguela A, Moya-Quiles MR, Blanco-García R, Martínez-Banaclocha H, García-Alonso AM, Alvarez-López MR, Martínez-Escribano JA. Campillo JA, et al. Immunogenetics. 2013 May;65(5):333-43. doi: 10.1007/s00251-013-0682-0. Epub 2013 Jan 31. Immunogenetics. 2013. PMID: 23370861
Immunological Risk Stratification of Bladder Cancer Based on Peripheral Blood Natural Killer Cell Biomarkers.
Guillamón CF, Gimeno L, Server G, Martínez-Sánchez MV, Escudero JF, López-Cubillana P, Cabezas-Herrera J, Campillo JA, Abellan DJ, Martínez-García J, Martínez-Escribano J, Ferri B, López-Álvarez MR, Moreno-Alarcón C, Moya-Quiles MR, Muro M, Minguela A. Guillamón CF, et al. Among authors: lopez alvarez mr. Eur Urol Oncol. 2021 Apr;4(2):246-255. doi: 10.1016/j.euo.2019.04.009. Epub 2019 May 14. Eur Urol Oncol. 2021. PMID: 31411976
TGF-beta1 gene polymorphism in liver graft recipients.
Gómez-Mateo J, Marin L, López-Alvarez MR, Moya-Quiles MR, Miras M, Marin-Moreno I, Botella C, Parrilla P, Alvarez-López MR, Muro M. Gómez-Mateo J, et al. Transpl Immunol. 2006 Dec;17(1):55-7. doi: 10.1016/j.trim.2006.09.011. Epub 2006 Sep 28. Transpl Immunol. 2006. PMID: 17157217
Influence of human leukocyte antigen mismatching on rejection development and allograft survival in liver transplantation: is the relevance of HLA-A locus matching being underestimated?
Muro M, López-Álvarez MR, Campillo JA, Marin L, Moya-Quiles MR, Bolarín JM, Botella C, Salgado G, Martínez P, Sánchez-Bueno F, López-Hernández R, Boix F, Bosch A, Martínez H, de la Peña-Moral JM, Pérez N, Robles R, García-Alonso AM, Minguela A, Miras M, Alvarez-López MR. Muro M, et al. Transpl Immunol. 2012 Mar;26(2-3):88-93. doi: 10.1016/j.trim.2011.11.006. Epub 2011 Nov 23. Transpl Immunol. 2012. PMID: 22129495 Clinical Trial.
Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing.
Martínez-Sánchez MV, Periago A, Legaz I, Gimeno L, Mrowiec A, Montes-Barqueros NR, Campillo JA, Bolarin JM, Bernardo MV, López-Álvarez MR, González C, García-Garay MC, Muro M, Cabañas-Perianes V, Fuster JL, García-Alonso AM, Moraleda JM, Álvarez-Lopez MR, Minguela A. Martínez-Sánchez MV, et al. Oncoimmunology. 2015 Oct 29;5(4):e1093721. doi: 10.1080/2162402X.2015.1093721. eCollection 2016 Apr. Oncoimmunology. 2015. PMID: 27141379 Free PMC article.
33 results